CBD Life Sciences Inc. (CBDL) Announces President Trump Confirms Marijuana Rescheduling Is Under Consideration
CBD Life Sciences (OTC:CBDL) reports that President Trump's administration is actively considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential regulatory shift could transform the $30+ billion cannabis market by eliminating IRS Section 280E restrictions and opening doors for institutional investment.
The rescheduling would enable cannabis companies to deduct ordinary business expenses, improve net margins, and facilitate access to banking services. With nearly 70% of Americans supporting legalization, CBDL is positioning itself through retail expansion, including recent approval for sales on Walmart Marketplace, to capitalize on the anticipated industry growth following regulatory reform.
CBD Life Sciences (OTC:CBDL) riferisce che l'amministrazione del Presidente Trump sta valutando seriamente di ricollocare la marijuana dalla Schedule I alla Schedule III del Controlled Substances Act. Questo cambiamento normativo potrebbe rivoluzionare il mercato della cannabis da oltre 30 miliardi di dollari eliminando le limitazioni dell'IRS Section 280E e favorendo l'ingresso degli investitori istituzionali.
La riclassificazione consentirebbe alle aziende del settore di dedurre le normali spese operative, migliorare i margini netti e agevolare l'accesso ai servizi bancari. Con il quasi 70% degli americani a favore della legalizzazione, CBDL si sta preparando espandendo la sua presenza retail, incluso il recente via libera alle vendite su Walmart Marketplace, per sfruttare la crescita prevista dopo la riforma normativa.
CBD Life Sciences (OTC:CBDL) informa que la administración del presidente Trump está considerando activamente reclasificar la marihuana de la Schedule I a la Schedule III según el Controlled Substances Act. Este posible cambio regulatorio podría transformar el mercado del cannabis de más de 30.000 millones de dólares al eliminar las restricciones de la Sección 280E del IRS y abrir la puerta a la inversión institucional.
La reclasificación permitiría a las compañías cannábicas deducir los gastos ordinarios de negocio, mejorar los márgenes netos y facilitar el acceso a servicios bancarios. Con casi el 70% de los estadounidenses apoyando la legalización, CBDL se está posicionando mediante la expansión minorista, incluida la reciente aprobación para vender en Walmart Marketplace, para capitalizar el crecimiento esperado tras la reforma regulatoria.
CBD Life Sciences (OTC:CBDL)는 트럼프 대통령 행정부가 마리화나를 통제물질법(Controlled Substances Act)상 Schedule I에서 Schedule III로 재분류하는 방안을 적극 검토 중이라고 보고했습니다. 이러한 규제 변화는 300억 달러 이상의 대마(칸나비스) 시장을 IRS 섹션 280E 제한 해소와 기관 투자 유입 가능성으로 인해 크게 바꿀 수 있습니다.
재분류가 이뤄지면 칸나비스 기업들은 통상적 사업 비용을 비용으로 공제할 수 있어 순이익률이 개선되고 은행 서비스 이용도 원활해집니다. 미국인의 거의 70%가 합법화를 지지하는 가운데, CBDL은 Walmart Marketplace 판매 승인 등 소매 확장을 통해 규제 개편 후 예상되는 산업 성장에 대비하고 있습니다.
CBD Life Sciences (OTC:CBDL) indique que l'administration du président Trump envisage activement de reclasser le cannabis de la Schedule I à la Schedule III en vertu du Controlled Substances Act. Ce changement réglementaire potentiel pourrait transformer le marché du cannabis de plus de 30 milliards de dollars en supprimant les restrictions de l'IRS Section 280E et en ouvrant la porte aux investissements institutionnels.
Le reclassement permettrait aux entreprises du secteur de déduire leurs dépenses professionnelles ordinaires, d'améliorer leurs marges nettes et de faciliter l'accès aux services bancaires. Avec près de 70 % des Américains favorables à la légalisation, CBDL se positionne en élargissant sa présence retail, y compris la récente approbation pour des ventes sur Walmart Marketplace, afin de tirer parti de la croissance prévue suite à la réforme réglementaire.
CBD Life Sciences (OTC:CBDL) berichtet, dass die Regierung von Präsident Trump aktiv erwägt, Marihuana vom Schedule I in Schedule III des Controlled Substances Act umzustufen. Dieser mögliche regulatorische Schritt könnte den mehr als 30 Milliarden Dollar schweren Cannabismarkt verändern, indem er die Beschränkungen durch IRS Section 280E aufhebt und institutionelle Investitionen ermöglicht.
Die Umstufung würde Cannabisunternehmen erlauben, gewöhnliche Betriebsausgaben abzusetzen, die Nettomargen zu verbessern und den Zugang zu Bankdienstleistungen zu erleichtern. Da fast 70% der Amerikaner die Legalisierung unterstützen, positioniert sich CBDL durch den Ausbau des Einzelhandels, einschließlich der jüngsten Zulassung für Verkäufe im Walmart Marketplace, um vom erwarteten Wachstum der Branche nach der Regulierung zu profitieren.
- Potential elimination of IRS Section 280E restrictions could significantly improve company margins
- Recent approval for sales on Walmart Marketplace expands retail presence
- Possible access to new institutional capital and banking services if rescheduling occurs
- Positioned to benefit from potential $30+ billion market opportunity
- Current Schedule I status still restricts business operations
- Rescheduling consideration is not guaranteed to result in actual policy change
- Company success heavily dependent on regulatory reform
"A shift to Schedule III could unlock a
SCOTTSDALE, ARIZONA / ACCESS Newswire / September 3, 2025 / CBD Life Sciences Inc. (OTC:CBDL), a leader in the development and sale of high-quality CBD and wellness products, is pleased to announce that President Donald Trump has confirmed his administration is actively considering the rescheduling of marijuana under the Controlled Substances Act. This announcement, highlighted in a recent JD Supra legal analysis, signals what may be the most pivotal regulatory moment in the history of the cannabis industry.
The administration is reviewing a proposal to reclassify cannabis from Schedule I to Schedule III, which would:
Deliver billions in tax relief: The elimination of IRS Section 280E restrictions would allow cannabis companies to deduct ordinary business expenses, improving net margins by double digits and freeing up billions in reinvestment capital across the sector.
Unlock capital markets: Banks, lenders, and institutional investors-previously sidelined due to regulatory risk-would gain clearance to enter the cannabis space, fueling an unprecedented wave of financing, credit, and equity growth.
Elevate cannabis as legitimate medicine: Federal recognition of marijuana's medical value would boost physician confidence, accelerate clinical trials, and enhance credibility with healthcare providers and patients alike.
Catalyze M&A and consolidation: Regulatory clarity would supercharge mergers, acquisitions, and strategic alliances, positioning leading companies like CBDL to seize early-mover advantage.
Ignite investor sentiment: Cannabis equities have already rallied on rescheduling optimism. A formal reclassification could spark another surge, creating generational wealth opportunities for early shareholders.
Why This Matters for CBD Life Sciences Inc.
CBD Life Sciences Inc. stands at the forefront of this coming wave. With proven retail traction, recent approvals for sale on Walmart Marketplace, and a growing pipeline of CBD and wellness innovations, the company is positioned to scale rapidly once federal restrictions ease.
"This is the moment we've been preparing for," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "The rescheduling of cannabis would remove historic barriers that have limited our industry's growth. For CBDL, it means the ability to expand faster, compete more effectively, and deliver greater long-term value for our shareholders."
Investor Highlights
President Trump confirms marijuana rescheduling is under active review.
Federal reform could unleash a
$30 + billion U.S. cannabis market opportunity.IRS 280E tax relief expected to save the industry billions annually.
Expanded access to institutional capital, banking, and financing.
Growing public approval of legalization with nearly
70% of Americans in support.CBDL is already executing growth strategy with retail expansion and product innovation.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC: CBDL) is a publicly traded company dedicated to delivering innovative, high-quality CBD and wellness products. Through its wholly owned subsidiary, The CBD Vault, the company develops, markets, and distributes a wide range of CBD tinctures, topicals, edibles, and wellness solutions available through retail and online channels.
Link To Article 1 : https://www.jdsupra.com/legalnews/president-trump-confirms-marijuana-7853330/#:~:text=President%20Trump's%20renewed%20focus%20on,financial%20relief%20for%20cannabis%20businesses
Link To Article 2 : https://www.cnbc.com/2025/08/11/cannabis-stocks-trump-considering-reclassification-weed.html
About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is an innovative health and wellness company committed to the research, development, and distribution of premium cannabidiol (CBD) products through its core brand, CBD Vault. From topicals and tinctures to wellness beverages and skincare solutions, CBDL is building a portfolio of products designed for maximum efficacy, transparency, and consumer trust.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What would marijuana rescheduling to Schedule III mean for CBDL stock?
How would the potential cannabis rescheduling affect CBDL's tax situation?
What is CBDL's current retail expansion strategy?
How large is the potential market opportunity for CBDL if marijuana is rescheduled?
What percentage of Americans support cannabis legalization according to CBDL's report?
